ABSTRACT: Introduction: This study analyzes and describes atypical presentations of Charcot-Marie-Tooth disease type 4C (CMT4C). Methods: We present clinical and physiologic features of 5 patients with CMT4C caused by biallelic private mutations of SH3TC2. Results: All patients manifested scoliosis, and nerve conduction study indicated results in the demyelinating range. All patients exhibited signs of motor impairment within the first years of life. We describe 2 or more different genetic diseases in the same patient, atypical presentations of CMT, and 3 new mutations in CMT4C patients. Discussion: A new era of unbiased genetic testing has led to this small case series of individuals with CMT4C and highlights the recognition of different genetic diseases in CMT4C patients for accurate diagnosis, genetic risk identification, and therapeutic intervention. The phenotype of CMT4C, in addition, appears to be enriched by a number of features unusual for the broad CMT category.
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Charcot-Marie-Tooth disease (CMT) is a group of clinically and genetically heterogeneous hereditary motor and sensory neuropathies with an overall prevalence of 1 in 2,500. Patients present with predominantly distal weakness, muscle atrophy, and sensory loss. 1 Autosomal recessive childhoodonset CMT neuropathies are less common than the autosomal dominant CMT neuropathies. 2 CMT type 4C (CMT4C) appears to be the most prevalent (18%) autosomal recessive CMT subtype. 3, 4 CMT4C is caused by recessive mutations of the SH3TC2 gene, most commonly by predicted protein null (frameshift and nonsense) mutations 4 and rarely by protein sequence changing missense mutations. This gene encodes an SH3 domain and multiple tetratricopeptide repeats (SH3TC2). It is expressed in myelinating Schwann cells and localizes to the perinuclear recycling endosomes (RE) and cell membrane. 5 The clinical spectrum of CMT4C appears to be broad in contrast to the slowly progressive distally symmetric phenotype of most forms of CMT. Common features of CMT4C include childhood onset, thoracic spine scoliosis, moderate-to-severe neuropathy, and cranial nerve deficits including impairment of oculomotor, facial, auditory, and hypoglossal nerves. 2, 6, 7 Small groups of individuals sharing a common genotype manifest phenotype variation, suggesting a role for other genetic or environmental factors in phenotypic expression. 6, 7 Here we report 5 patients with atypical phenotypes associated with SH3TC2 mutations to add weight to the evolving understanding of the CMT4C phenotype as a disorder with both consistent and heterogeneous features uncommon for typical CMT.
MATERIALS AND METHODS
Five individuals diagnosed with SH3TC2 mutations were evaluated at the University of Iowa (patients 1, 2, 4), Johns Hopkins University (patient 2), Wayne State University (patient 3), and the National Institutes of Health (patient 5). Skeletal muscle strength was tested by using the Medical Research Council (MRC) grading system from 0 (no movement) to 5 (normal strength). Four participants were also evaluated by a modified CMT neuropathy score that assesses CMT-related signs, symptoms, and electrophysiologic features, with scores of 0-10 marking mild impairment, 11-20 moderate impairment, and >21 significant impairment. 8 Nerve conduction studies (NCS) were obtained routinely Additional supporting information may be found in the online version of this article.
from the left ulnar motor nerve and left radial sensory nerve, unless otherwise specified. Ulnar and radial responses were used because peroneal and sural potentials are typically absent even in demyelinating CMT. 8 Mutation Identification. The location of each SH3TC2 mutation is described according to the GenBank coding DNA reference sequence NM_024577.3. Mutations were identified by unbiased testing means in all participants, a targeted commercial CMT panel in 3 patients and commercial whole exome sequencing in 1 patient. Homozygosity mapping (The Children's Hospital of Philadelphia, Philadelphia, PA) and exome sequencing (NIH Intramural Sequencing Center, Bethesda, MD) were conducted to identify the mutation in patient 5. Sanger sequencing, performed in a Clinical Laboratory Improvement Amendmentscertified laboratory (Athena Diagnostics, Worcester, MA), confirmed the mutations identified by exome sequencing.
Functional Studies. To determine whether the new missense mutation in patient 5 affected SH3TC2 localization or RE morphology, HA-tagged wild type(WT) and Tyr680Cys SH3TC2 proteins were coexpressed with Rab11eGFP in lipofected rat Schwann cells obtained from P3 Sprague-Dawley sciatic nerves, as described previously. 9 The cells were seeded in 4-well dishes and lipofected with FuGene HD (Promega, Madison, WI), according to the manufacture's description. After 48 h, cultures were fixed for 15 min in 4% paraformaldehyde, permeabilized for 5 min in phosphatebuffered saline (PBS) 0.2% triton X-100, and blocked for 1 h with PBS containing 5% normal goat serum and 0.2% Triton X-100. The cells were incubated overnight at 48C with HA (Cell Signaling Technology, Beverly, MA) and green fluorescence protein (GFP; Invitrogen, Carlsbad, CA) antibodies diluted in blocking solution. Detection of primary antibodies was conducted with antimouse Alexa 594 and antirabbit Alexa 488 (Invitrogen). Confocal images were obtained with a Leica SP5 microscope (Leica Microsystems, Wetzlar, Germany). Fifty cells for WT SH3TC2 and sixty cells for Tyr680Cys mutant were analyzed. By using stacks of confocal images (0.13-mm intervals), the Rab11e GFP 1 surface was calculated in Imaris (Bitplane, Zurich, Switzerland) software and compared with the total Schwann cell body surface to estimate the percentage of the surface area of the RE. All analyses were conducted by blinded investigators.
Standard Protocol Approvals and Patient Consents. All human and animal studies were approved by the appropriate ethics committee and relevant institutional review boards and were performed in accordance with the ethical standards laid down in the 1964 Declaration of Helsinki and its later amendments. Informed written assent and consent were obtained from each participant and parent or guardian prior to their inclusion in the study.
RESULTS

Patient 1.
History. A 12-year-old girl born of asymptomatic parents of Chinese descent had delayed motor developmental milestones. She crawled by 14 months and preferred to cruise (i.e., attempting to ambulate while holding onto furniture) until age 3 years. By age 7 years, she had developed hand weakness, scoliosis, calf cramps, and left hip dysplasia. By age 8 years, she had lost the previously acquired ability to run.
She was diagnosed with short-chain acyl-coenzyme A dehydrogenase deficiency (SCADD), a rare inborn error of mitochondrial fatty acid disorder during infancy. She did not manifest failure to thrive, low blood sugar, or lethargy. She was treated with carnitine, which she continued over the years.
Clinical Exam. On examination at age 12 years, she had horizontal nystagmus in the left eye, mild dysarthria, distal greater than proximal muscle weakness and atrophy, and absent vibratory sensation up to the knees. She could not toe, heel, or tandem walk and had a bilateral steppage gait. She had thoracic scoliosis (Supp. Info. Table 1) .
Investigations. NCSs were consistent with a demyelinating motor and sensory neuropathy (Table 1) . We identified a novel homozygous SH3TC2 c.323 0C>G, p. Ser1077Ter mutation predicted to be disease causing because it truncates the C-terminus and most likely interferes with the translation of the functional SH3TC2 protein. 10 This mutation is not reported in the Broad ExAc (Exome Aggregation Consortium) database (http://exac.broadinstitute. org/). History. An 18-year-old girl was born to asymptomatic parents of Native American and African American descent. Her family history was notable for frequent first trimester miscarriages in her mother and maternal aunt. In the first year of life, she manifested failure to thrive with multiple sinus and ear infections associated with low immunoglobulin E levels. At about age 10, she developed episodes of muscle weakness, frequent falls, ataxia, difficulty walking, and numbness lasting 2-3 days, sometimes associated with urinary retention. Examination during these episodes confirmed worsening of baseline length-dependent weakness and distal lower extremity large and small fiber sensory loss. The presence of patchy demyelinating features on NCS led to prolonged trials of intravenous immunoglobulin (IVIg) and corticosteroid therapy without a clear effect on her functional abilities or the frequency or severity of her episodes. Because of easy bruising, hematologic evaluation at age 7 years identified absence of measurable plasminogen activator inhibitor-1 (PAI-1) and von Willebrand type 2M. She had a spinal fusion at age 12 years for scoliosis, which was first noted at age 2 years. She developed unilateral sensorineural deafness at age 14 years. She had progressive worsening of a sensory ataxia over the years and lost the ability to ambulate independently by age 15. Clinical Exam. At age 4 months, she was noted to have pendular nystagmus. After her toddler years, she achieved the fifth percentile in height and weight. At age 5 years she had restricted upgaze. A neurological examination at age 18 years demonstrated pes planus and distal atrophy in her hands and feet. She had MRC grade 4 strength in foot dorsiflexion and 42 strength in hand intrinsic muscles. She had sensory loss to pinprick in her toes and loss to vibration up to her knees and elbows bilaterally. She was unable to heel, toe, or tandem walk; she had an ataxic gait (see Supp. Info. Table 1) .
Investigations. Cerebral spinal fluid (CSF) protein was elevated at 416 mg/dL at the onset of an episode at age 14 years, which decreased to 172 mg/ dL after 3 days of IVIg; cell count in CSF was normal. A sural nerve biopsy showed moderate to severe demyelinating polyneuropathy, no inflammation, and small onion bulbs. The NCS initially demonstrated a demyelinating polyneuropathy with side-toside and nerve-to-nerve variation and temporal dispersion, suggesting patchy involvement; repeat NCSs, however, showed a uniformly demyelinating process with no temporal dispersion or conduction block ( 4, 11, 12 and the maternally inherited c.3511C>T p.Arg1171Cys mutation. History. A 29-year-old woman was born to Turkish parents who were first cousins (Fig. 1) . She was sick at birth and hospitalized for an extended period of time for uncertain reasons. Early motor milestones were delayed as she walked at 1.5 years of age. She had multiple falls due to balance difficulties. Thoracic spine scoliosis was noted at age 3 years. She was diagnosed with retinitis pigmentosa at age 29 years when funduscopy, performed because of visual difficulties, identified bilateral pigment displacement, partial optic atrophy, and narrowed vessels. Her father was also diagnosed with retinitis pigmentosa (see pedigree in Fig. 1 ). The patient did not consent to genetic testing of retinitis pigmentosa.
Clinical Exam. At age 29 years, a neurological examination demonstrated limited visual fields with reported tunnel vision on examination, bilateral exotropia, distal greater than proximal muscle weakness and atrophy, reduced vibratory sense to the wrist and knees, and reduced pinprick at the toes. She could walk with mild foot drop but was unable to tandem or heel walk. (Supp. Info. Table 1) .
Investigations. NCS (Table 1) showed a predominantly demyelinating neuropathy. She had a normal electrocardiogram. Nerve biopsy showed onion bulbs with no inflammatory reaction. Genetic testing revealed a known homozygous pathogenic SH3TC2 frameshift c.1894_1897 delinsAAA mutation, p.E632fs. 14 
Patient 4.
History. A 37-year-old man of IrishItalian decent had delayed motor milestones and walked at age 16 months with balance difficulties. He could ride a bicycle but could not roller skate or ice skate. He had burning pain and paresthesias in his feet and ankles and was diagnosed with CMT at age 6 years. He developed scoliosis during childhood. He had a heel cord extension and tendon transfer in his left foot at age 12. Ventricular tachycardia was diagnosed in childhood, and cardiac ablation was performed in his teenage years. He was still able to exercise in the gym and to walk and bike frequently.
Clinical Exam. Examination at 37 years of age was significant for pes cavus and atrophy in his hands and feet. He had MRC 41 strength in foot dorsiflexion, plantar flexion, and eversion bilaterally. He had sensory loss to pinprick, vibration, and joint position sense up to his ankles and impaired sensation to pinprick up to his wrists. He was unable to heel, toe, or tandem walk. (Supp. Info. Table 1) .
Investigations. NCS results were consistent with a demyelinating sensorimotor neuropathy (Table  1) . A commercial genetic testing showed heterozygous SH3TC2 c.2860 C>T, p. Arg954Ter and c.2128 C>T, p.Gln710Ter mutations inherited on different alleles in trans arrangement; the p.Arg954Ter (R954X) mutation is known to be disease causing. 4, 11, 12 The p.Gln710Ter (Q710X) is a novel variant predicted to be pathogenic through protein truncation or nonsense-mediated mRNA decay. This variant is not detected in the National Heart, Lung, and Blood Institute exome sequencing project in approximately 6,500 individuals of European and African American ancestry. The Broad ExAc database reports a heterozygous allele count of 1/121,402, but no homozygotes were identified. Although this specific variant has not been reported previously, there are other pathogenic loss-offunction variants that have been reported in this gene. 15 
Patient 5.
History. A 40-year-old man was born at full term of nonconsanguineous Indian parents.
He had normal motor and verbal development. At age 5, he was noted to be a slow runner compared with his peers. He had difficulty rising from the floor and some difficulty in standing and walking. He had thoracic spine scoliosis. He underwent foot surgery to correct an ankle contracture at age 10 years. During his late-teen years, he noticed weakness in the upper extremities that caused difficulty lifting his arms above the shoulders and flexing his arms to bring a cup to the mouth. His handwriting at that time deteriorated, and he had trouble bending the thumbs and stapling documents. He also developed bilateral foot drop. During his 20s, he had difficulty rising from a chair and required support to climb stairs. He also developed deafness and had trouble with word pronunciation. He had difficulty whistling and blowing out candles. His mouth readily filled with saliva. His leg and arm weakness continued to worsen over the years. In his 30s, he required nightly noninvasive ventilatory support for respiratory insufficiency and carbon dioxide retention. Bilateral sensorineural deafness was noted. He did not report sensory or autonomic symptoms.
Clinical Exam. When evaluated at age 40 years, he had bilateral facial weakness; scoliosis of thoracic spine; and asymmetric, left greater than right, scapular winging. Muscle bulk was reduced in the lower legs, the forearms, and around the shoulders. There were no visible fasciculations and no visible tremor or myotonia. Muscle strength testing results showed bilateral upper and lower extremity weakness proximally and distally (Supp. Info. Table 1 ). Deep tendon reflexes were absent. Sensory examination results were normal except for diminished vibration on the toes. His gait was a broad-based waddle with foot drop.
Investigations. Creatine kinase levels were normal. NCS demonstrated a predominantly motor neuropathy with nerve conduction velocities in the demyelinating range (Table 1) . Needle electromyography showed chronic denervation with reinnervation in the deltoid, quadriceps, first dorsal interosseous, tibialis anterior, lumbar paraspinal muscles, and trapezius muscle. Exome sequencing identified a homozygous SH3TC2 c.2039A>G p.Tyr680Cys mutation located adjacent to previously reported mutations in a mutation hotspot in exon 11, which encodes a protein interaction domain containing tetratricopeptide repeat motifs and was confirmed by Sanger sequencing. (See Supp. Info Fig. 1a,b,c) . 4 The Tyr680Cys SH3TC2 did not affect intracellular SH3TC2 localization or RE morphology in transfected Schwann cells (Supp. Info. Fig. 1d ). Both sorting intolerant from tolerant (SIFT) and polymorphism phenotyping-2.2.2. (HumVar) predicted this mutation to be pathogenic. The Tyr680Cys variant is not found in the single nucleotide polymorphism database (dbSNP; https://www.ncbi.nlm.nih.gov/projects/ SNP/). The Broad ExAc database includes a heterozygous allele count 2/121,374, but the homozygotes were not detected. No mutations were identified in other candidate neuropathy genes in the exome. We found several regions of extended homozygosity (3 Mb), including the SH3TC2 locus encompassing at least 197 Mb (6% or 1/16 of the genome) by SNP array-based homozygosity, suggesting that his parents were first cousins. Parental DNA was not available for testing. He was their only child, and other family members were not available for segregation analysis. He did not provide consent for a nerve biopsy. The clinically overlapping syndrome of facioscapulohumeral muscular dystrophy types 1 and 2 (MIM 158900 and 158901) was ruled out by genetic testing. 5 
DISCUSSION
We describe CMT4C patients with 2 or more independent genetic disease processes, with atypical clinical presentations, and new SH3TC2 mutations in our case series. Individual diagnosis of CMT4C patients is challenging because of considerable intrafamilial and interfamilial clinical variability. The diagnostic challenge was further compounded in sporadic CMT4C patients because of the presence of additional extremely rare inherited disorders such as SCADD, 16 retinitis pigmentosa, 17 von Willebrand type 2M, 18 and PAI-1 deficiency. 19 When considering our patients together with previous reports from the literature, it seems appropriate for CMT4C to be considered an atypical form of CMT. It is not clear why there is increased phenotypic variability in CMT4C, but this could be secondary to cryptogenic modifiers or to the diversity of SH3TC2 protein function. SH3TC2 has 10 tetratricopeptide repeat domains and multiple regulatory functions, each of which could be uniquely targeted by the diverse array of identified mutations. 7 Our patients were from diverse ethnic backgrounds, including Native American, African American, Chinese, and Indian, in which CMT4C has been rarely or not yet reported. All had the core features of CMT4C, including demyelinating neuropathy with early-onset scoliosis. There are reports of CMT4C patients presenting with side-to-side asymmetry, lack of scoliosis, and phenotypic variability despite identical genotypic mutations. 6, 7, 15, 20, 21 Sleep apnea, respiratory failure, and cranial nerve involvement such as nystagmus and facial weakness have also been described in some patients. 4 Cardiac arrhythmias have not yet been reported in CMT4C. Ventricular tachycardia in the pediatric population is likely a benign condition and unrelated to CMT. Retinitis pigmentosa associated with demyelinating neuropathy of childhood onset is typical of Refsum disease and polyneuropathy, hearing loss, ataxia, retinitis pigmentosa, and cataract (PHARC) syndrome, which are rare autosomal recessive neurodegenerative disorders. 22, 23 In our patient, Refsum disease and PHARC syndrome were ruled out clinically. It is likely that retinitis pigmentosa was an autosomal dominant or Xlinked dominant disease because her father was also affected. Whereas proximal muscle weakness and scapular winging have been reported in rare CMT4C patients, 17 we report an facioscapulohumeral muscular dystrophy phenotype in patient 5. Coexisting rare recessive bleeding disorders, PAI-1 deficiency, and von Willebrand type 2M disease, are unusual associations in a patient with CMT4C. Clinically, SCADD and CMT4C share neurological features of growth and developmental delay, muscle weakness, and scoliosis. It is not yet known whether SCADD affects peripheral nerve function and worsens phenotype of CMT4C.
In a patient with compound heterozygous Arg954Ter and Arg1171Cys mutations, we observed recurrent acute episodes of worsening muscle weakness and numbness with elevated CSF protein and enlarged nerves, which may or may not represent superimposed inflammatory neuropathy. The variable nature of the episodes, overall trend to increasing functional debility, and inconsistent response to therapy make determination of an inflammatory contribution to pathology uncertain. An unclear contribution of inflammatory neuropathy to functional loss has also been reported in a patient with CMT4C due to Arg954Ter homozygous mutation. 24 In our case and in the previous reported case, the question of an inflammatory component is raised but not entirely confirmed.
Only 1 patient in our case series had a pedigree compatible with autosomal recessive inheritance, and she had a homozygous known frameshift mutation resulting in premature truncation and loss of functional SH3TC2 protein. In patients without parental consanguinity, compound heterozygosity for 2 different mutations is the most likely genetic basis for recessive disorders as exemplified by 2 participants in this series. To be functionally equivalent to homozygosity, it is important to demonstrate that these mutations affect different copies of a gene, which was shown by testing parental DNA in patient 2 and by an allele-specific polymerase chain reaction in patient 4.
In patient 5, a nonconsanguineous sporadic patient, an SNP array-based whole-genome homozygosity mapping confirmed recessive inheritance and led to the identification of the novel Tyr680Cys mutation in SH3TC2 gene by exome sequencing. Next-generation sequencing including candidate gene panels or whole-exome sequencing can be the most comprehensive and cost effective diagnostic testing approach in genetically heterogeneous CMT neuropathies. However, interpretation of the variants of yet unknown significance, as described in one of our patients, remains a challenging and time-consuming process. Sequencing of a larger number of unaffected individuals is required to differentiate diseasecausing mutations from common polymorphisms. 25 Family segregation analysis, clinical phenotyping, and laboratory-based validation of functional impact of the variants are essential to establish pathogenicity of these variants. The deep variant databases of over 70,000 individuals available on the Broad ExAg Consortium browser (http://exac.broadinstitute. org/) can provide the information on the frequency and the impact of the identified variants across populations.
We report 3 novel SH3TC2 mutations including homozygous Tyr680Cys and Ser1077Ter mutations and a heterozygous Gln710Ter mutation that coexisted with the common Arg954Ter mutation in this case series. Premature truncating mutations are predicted to result in loss of functional SH3TC2 protein.
Studies of missense mutations are important in lossof-function disorders because these mutations can yield unique insights into the underlying molecular mechanisms in rare diseases. SH3TC2 is specifically expressed in Schwann cells and has been shown to target the RE by associating with the small guanosine triphosphatase Rab11. 5, [26] [27] [28] Mistargeting of SH3TC2 away from RE has been proposed as a disease mechanism in CMT4C. 28 It has been shown that SH3TC2 condenses the RE, whereas the CMT4C-associated Asn881Ser mutant impairs RE condensation. 5 In contrast, we found that Tyr680Cys mutation does not affect the RE morphology or the RE targeting of SH3TC2. Our findings indicate that the Tyr680Cys mutation likely causes hypomyelination by affecting the interaction between SH3TC2 and protein(s) other than Rab11, for example, surface receptors in the schwann cell (SC) membrane. 28, 29 Additional functional studies of this missense mutation will clarify its pathophysiological consequences in SCs and may more generally provide additional insight into glial cell biology.
In conclusion, phenotypic variability and additional comorbidities have the potential to confound the diagnostic process in CMT4C patients. Whole-exome sequencing improves the diagnostic yield among patients with atypical phenotypes and coexisting diseases. It is essential to recognize coexisting diseases in patients with CMT4C for genetic risk assessment, prognosis, and potential therapeutic interventions.
